论文部分内容阅读
目的观察丝裂霉素C、噻替哌预防浅表性膀胱癌术后复发的远期疗效。方法将1998年10月至2003年10月的84例浅表性膀胱癌患者随机分为丝裂霉素C组(41例)和噻替哌组(43例),对比观察两组的肿瘤术后复发率。结果丝裂霉素C组和噻替哌组术后肿瘤复发率分别为41.5%和46.5%。经统计学处理,两组的肿瘤复发率差异无统计学意义(P>0.05)。结论浅表性膀胱癌术后经过丝裂霉素C、噻替哌灌注治疗均可以有效地减少肿瘤复发,二者疗效近似。
Objective To observe the long-term efficacy of mitomycin C and thiotepa to prevent postoperative recurrence of superficial bladder cancer. Methods Eighty-four patients with superficial bladder cancer from October 1998 to October 2003 were randomly divided into mitomycin C group (41 cases) and thiotepa group (43 cases) The recurrence rate. Results The postoperative tumor recurrence rates of mitomycin C group and thiotepa group were 41.5% and 46.5% respectively. After statistical analysis, there was no significant difference in tumor recurrence rate between the two groups (P> 0.05). Conclusions The treatment of superficial bladder cancer after mitomycin C and thiotepa perfusion can effectively reduce the tumor recurrence, and the curative effect is similar.